RachelGrishamMD

Gynecologic Cancer, Hematologic Oncology

Associate Attending, Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College; Section Head of Ovarian Cancer; Director Gynecologic Medical Oncology MSKCC Westchester

Request Appointment

Overview of Dr. Grisham

Dr. Rachel Grisham is an oncologist in West Harrison, NY and is affiliated with Memorial Sloan Kettering Cancer Center. She received her medical degree from Duke University School of Medicine and has been in practice 11 years. Dr. Grisham accepts several types of health insurance, listed below. She is one of 497 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She has more than 80 publications and over 500 citings.

Office
500 Westchester Avenue
West Harrison, NY 10604
Book by Phone+1(469) 530-2420

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Massachusetts General HospitalResidency, Internal Medicine, 2006 - 2009
Duke University School of MedicineClass of 2006

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2009 - 2026
CT State Medical License 2023 - 2025
NJ State Medical License 2019 - 2025
NC State Medical License 2020 - 2022
MA State Medical License 2008 - 2009
American Board of Internal Medicine Medical Oncology

Clinical Trials

Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies Start of enrollment: 2013 Nov 05
Completed
Phase 2
A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone Start of enrollment: 2019 May 02
Active, not recruiting
Phase 2
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Start of enrollment: 2020 May 07
Recruiting
Phase 1
Nirogacestat in Ovarian Granulosa Cell Tumors Start of enrollment: 2022 Aug 30
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer Start of enrollment: 2023 Mar 15
Recruiting
Phase 2
Roles: Principal Investigator, Contact
A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy Start of enrollment: 2024 Jan 26
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Association between genomic instability score and progression-free/overall survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer.
Stephen Graves, Mackenzie W Sullivan, Anusha Adkoli, Qin Zhou, Alexia Iasonos
Gynecologic Oncology. 2024-12-07
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients w...
Rachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, Kathleen Nadine Moore, Michel Fabbro
International Journal of Gynecological Cancer. 2024-10-07
1 citations
Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, ...
Sarah Andres, Lindsey Finch, Alexia Iasonos, Qin Zhou, Jeffrey Girshman
Gynecologic Oncology. 2024-10-01

Lectures

Low Grade Ovarian Carcinoma: Fitting the Square Peg into the Round Hole
ASCO Annual Meeting 2019 - Chicago, IL - 5/3/2019
Gynecologic Cancer
ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019

Press Mentions

Updated Data from Part a of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and DefactinibMay 25th, 2023
Targeting Progesterone in Hormonally Responsive Ovarian CancerDecember 10th, 2019
Context Therapeutics and World-Renowned Cancer Center Announce a Phase 2 Trial for Apristor® in Progesterone Receptor Positive Gynecological CancersMay 2nd, 2019
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
Empire BCBS HMO
Empire BCBS PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment